Annals of Behavioral Medicine

A randomized controlled trial to prevent depression and ameliorate insulin resistance in adolescent girls

Abstract

Background

Prospective data suggest depressive symptoms worsen insulin resistance and accelerate type 2 diabetes (T2D) onset.

Purpose

We sought to determine if reducing depressive symptoms in overweight/obese adolescents at-risk for T2D would increase insulin sensitivity and mitigate T2D risk.

Method

We conducted a parallel-group randomized controlled trial comparing a 6-week cognitive-behavioral (CB) depression prevention group with a 6-week health education (HE) control group in 119 overweight/obese adolescent girls with mild-to-moderate depressive symptoms (Center for Epidemiological Studies-Depression Scale [CES-D] ≥16) and T2D family history. Primary outcomes were baseline to post-intervention changes in CES-D and Whole Body Insulin Sensitivity Index (WBISI), derived from 2-hour oral glucose tolerance tests. Outcome changes were compared between groups using ANCOVA, adjusting for respective baseline outcome, puberty, race, facilitator, T2D family history degree, baseline age, adiposity, and adiposity change. Multiple imputation was used for missing data.

Results

Depressive symptoms decreased (p<0.001) in CB and HE from baseline to post-treatment, but did not differ between groups (ΔCESD −12 vs. −11, 95% CI difference −4 to +1, p=0.31). Insulin sensitivity was stable (p>0.29) in CB and HE (ΔWBISI 0.1 vs. 0.2, 95% CI difference −0.6 to +0.4, p=0.63). Among all participants, reductions in depressive symptoms were associated with improvements in insulin sensitivity (p=0.02).

Conclusions

Girls at-risk for T2D displayed reduced depressive symptoms following 6 weeks of CB or HE. Decreases in depressive symptoms related to improvements in insulin sensitivity. Longer-term follow-up is needed to determine if either program causes sustained decreases in depressive symptoms and improvements in insulin sensitivity.

READ FULL ARTICLE HERE